In FDA obesity drug battle with compounders, Texas court allows Novo Nordisk to weigh in
As a federal court in Texas hears a case pitting the FDA versus compounders who want to continue to manufacture cheaper knockoff versions of popular weight loss drugs, Novo Nordisk will not have to | A federal district court in Texas will allow Novo Nordisk to intervene in a lawsuit pitting compounders against the FDA.
Pfizer on Thursday named James List as the head of the drugmaker's Internal Medicine portfolio, where he will oversee the ...
Two recent documents—one from the FDA, the other from a commission organized by The Lancet Diabetes & Endocrinology—indicate ...
Obesity and pharmacology experts are warning about hidden safety risks and efficacy issues for many types of medications in ...
USA TODAY on MSN13d
Generic Wegovy, Ozempic compounds may become harder to get as FDA removes drug from shortage listThe sale of compounded versions of Eli Lilly's LLY.N rival obesity and diabetes drugs, Zepbound and Mounjaro, was banned in ...
A licensing deal with Denmark’s Gubra gives the immunology giant control of an experimental therapy that could compete with ...
India's largest drugmaker by revenue Sun Pharmaceutical is aiming to launch its experimental anti-obesity and type 2 diabetes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback